Clinical trial data show that galantamine maintains patients’ cognitive functioning for 12 months and suggests that galantamine may have additional benefits for AD patients compared with other acetylcholinesterase inhibitors [50]. This evidence concerns the gene ACHE and Alzheimer disease.